Ex vivo modifiable medicament release-sites final dosage form

• US 20100069821A1
• Filed: 04/29/2009
• Published: 03/18/2010
• Est. Priority Date: 09/16/2008
• Status: Abandoned Application

• Current Assignee: Deep Science LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Wood, Victoria Y.H., Ishikawa, Muriel Y., Boyden, Edward S., Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Sweeney, Elizabeth A., Bangera, Mahalaxmi Gita
• Application Number:
  US12/387,323
• Publication Number:
  US 20100069821A1
• Time in Patent Office: Days
• US Class Current: 604/20
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/127 Liposomes

Abstract

Described embodiments include a final dosage form, an article of manufacture, and method. A described final dosage form includes a dosage portion having a medicament, and a site and the medicament in a first association. In the first association, the medicament has a first bioavailability. The first association of the site and the medicament is modifiable ex vivo to a second association an exposure to a stimulus, wherein the medicament has a second bioavailability. The final dosage form includes another dosage portion having another medicament, and another site and the another medicament in another first association. In the another first association, the another medicament has another first bioavailability. The another first association is modifiable ex vivo to another second association of the another site and the another medicament by an exposure to another stimulus, wherein the another medicament has another second bioavailability.

Claims

1. A final dosage form for administering medicament to an animal, the final dosage form comprising:

a dosage portion having

a medicament; and

a site and the medicament in a first association wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal,

the first association of the site and the medicament modifiable ex vivo to a second association of the site and the medicament by an exposure to a stimulus, wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal; and

another dosage portion having

another medicament; and

another site and the another medicament in another first association wherein the another medicament has another first bioavailability to the animal if the final dosage form is administered to the animal,

the another first association of the another site and the another medicament modifiable ex vivo to another second association of the another site and the another medicament by an exposure to another stimulus, wherein the another medicament has another second bioavailability to the animal if the final dosage form is administered to the animal.

2. The final dosage form of claim 1, wherein the dosage portion includes a particle.

3. The final dosage form of claim 1, wherein the dosage portion includes a polymeric material.

4. The final dosage form of claim 1, wherein the another dosage portion includes another particle.

5. The final dosage form of claim 1, wherein the site and the medicament in a first association includes:

a site of a particle or polymeric in a first association with the medicament.

6. The final dosage form of claim 1, wherein the site and the medicament in a first association includes:

a site of a particle or polymeric encapsulating the medicament and in a first association with the medicament.

7. The final dosage form of claim 1, wherein the site and the medicament in a first association includes:

a particle or polymeric site that at least one of engages, retains, or binds the medicament in a first association.

8. The final dosage form of claim 1, wherein the another dosage portion includes another polymeric material.

9. The final dosage form of claim 1, wherein the first bioavailability to the animal includes:

the medicament is not bioavailable to the animal.

10. The final dosage form of claim 1, wherein the first bioavailability to the animal includes:

the medicament is bioavailable to the animal.

11. The final dosage form of claim 1, wherein the second bioavailability to the animal includes:

the medicament is not bioavailable to the animal.

12. The final dosage form of claim 1, wherein the second bioavailability to the animal includes:

the medicament is bioavailable to the animal.

13. The final dosage form of claim 1, wherein the another first bioavailability to the animal includes:

the another medicament is not bioavailable to the animal.

14. The final dosage form of claim 1, wherein the another first bioavailability to the animal includes:

the another medicament is bioavailable to the animal.

15. The final dosage form of claim 1, wherein the another second bioavailability to the animal includes:

the another medicament is not bioavailable to the animal.

16. The final dosage form of claim 1, wherein the another second bioavailability to the animal includes:

the another second medicament is bioavailable to the animal.

17. The final dosage form of claim 1, wherein the first bioavailability to the animal includes a first bioavailability characteristic and the second bioavailability to the animal includes a second bioavailability characteristic.

18. The final dosage form of claim 1, wherein the another first bioavailability to the animal includes another first bioavailability characteristic and the another second bioavailability to the animal includes another second bioavailability characteristic.

19. The final dosage form of claim 1, wherein the stimulus includes:

at least one of a mechanical stimulus, a non-ionizing radiation stimulus, an ionizing radiation stimulus, a chemical stimulus, an acoustic stimulus, an ultrasound stimulus, a radio wave stimulus, a microwave stimulus, a light wave stimulus, or a thermal stimulus.

20. The final dosage form of claim 1, wherein the another stimulus includes:

at least one of a mechanical stimulus, a non-ionizing radiation stimulus, an ionizing radiation stimulus, a chemical stimulus, an acoustic stimulus, an ultrasound stimulus, a radio wave stimulus, a microwave stimulus, a light wave stimulus, or a thermal stimulus.

21. A final dosage form for administering medicament to an animal, the final dosage form comprising:

a dosage portion having;

a medicament;

a site and the medicament in a first association wherein the medicament is substantially not bioavailable to the animal if the final dosage form is administered to the animal,

the first association of the site and the medicament modifiable ex vivo to a second association by an exposure to a stimulus, wherein the medicament is substantially bioavailable to the animal if the final dosage form is administered to the animal; and

another dosage portion having

another medicament;

another site and the another medicament in another first association wherein the another medicament is substantially not bioavailable to the animal if the final dosage form is administered to the animal,

the another first association of the site and the another medicament modifiable ex vivo to another second association by an exposure to another stimulus, wherein the another medicament is substantially bioavailable to the animal if the final dosage form is administered to the animal.

22. The final dosage form of claim 21, further comprising:

an outer layer encapsulating the first dosage portion and the second dosage portion.

23. A method of modifying a medicament bioavailability of a final dosage form for administering a medicament to an animal, wherein the final dosage form includes

a dosage portion having

a medicament;

and

a site and the medicament in a first association wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal,

the first association of the site and the medicament modifiable ex vivo to a second association of the site and the medicament by an exposure to a stimulus, wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal; and

another dosage portion having

another medicament; and

another site and the another medicament in another first association wherein the another medicament has another first bioavailability to the animal if the final dosage form is administered to the animal,

the another first association of the another site and the another medicament modifiable ex vivo to another second association of the another site and the another medicament by an exposure to another stimulus, wherein the another medicament has another second bioavailability to the animal if the final dosage form is administered to the animal;

the method comprising;

transforming the final dosage form into a selected medicament release state by initiating an ex vivo exposure of the first association of the site and the medicament or the another first association of the another site and the another medicament to a modification stimulus respectfully selected from the stimulus or the another stimulus.

24. The method of claim 23, wherein the transforming the final dosage form into a selected medicament release state by initiating an ex vivo exposure of the first association of the site and the medicament or the another first association of the another site and the another medicament to a modification stimulus respectfully selected from the stimulus or the another stimulus includes:

transforming the final dosage form into a selected medicament release state by initiating an ex vivo exposure of the first association of the site and the medicament and the another first association of the another site and the another medicament to the stimulus and the another stimulus.

25. The method of claim 23, further comprising:

receiving a signal indicative of a chosen medicament bioavailability of the final dosage form.

26. The method of claim 25, wherein receiving a signal indicative of a chosen medicament bioavailability of the final dosage form includes:

receiving a machine-initiated signal indicative of a chosen medicament bioavailability of the final dosage form.

27. The method of claim 25, wherein receiving a signal indicative of a chosen medicament bioavailability of the final dosage form includes:

receiving a signal responsive to human-initiated indication of a chosen medicament bioavailability of the final dosage form.

28. The method of claim 23, further comprising:

selecting a medicament-release state of the substance associated with the medicament or of the substance associated with the another medicament in response to the chosen medicament-bioavailability of the final dosage form.

29. The method of claim 28, wherein the selecting a medicament-release state of the substance associated with the medicament or of the substance associated with the another medicament in response to the chosen medicament-bioavailability of the final dosage form includes:

electronically selecting a medicament-release state of the substance associated with the medicament or of the substance associated with the another medicament in response to the chosen medicament-bioavailability of the final dosage form, the selecting a medicament-release state based on an electronically-stored database relating medicament-release state and medicament-bioavailability of the final dosage form, a computer-implemented decision table, a digitally-maintained final dosage form transformation table, or a digital library correlating medicament-release state and medicament-bioavailability of the final dosage form.

30. The method of claim 23, further comprising:

selecting the modification stimulus from the stimulus or the another stimulus in response to the selected medicament-release state.

31. The method of claim 30, wherein the selecting the modification stimulus from the stimulus or the another stimulus in response to the selected medicament-release state includes:

electronically selecting the modification stimulus from the stimulus or the another stimulus in response to the selected medicament-release state, the selecting the stimulus based on an electronically-stored database relating stimuli and medicament-release state of the final dosage form, a computer-implemented decision table, a digitally-maintained final dosage form transformation table, or a digital library correlating medicament-release state of the final dosage form and stimuli.

32. An article of manufacture comprising:

a dosage portion having

a medicament; and

a site and the medicament in a first association wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal,

the first association of the site and the medicament modifiable ex vivo to a second association of the site and the medicament by an exposure to a stimulus, wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal; and

another dosage portion having

another medicament; and

another site and the another medicament in another first association wherein the another medicament has another first bioavailability to the animal if the final dosage form is administered to the animal,

the another first association of the another site and the another medicament modifiable ex vivo to another second association of the another site and the another medicament by an exposure to another stimulus, wherein the another medicament has another second bioavailability to the animal if the final dosage form is administered to the animal; and

instructions specifying an ex vivo exposure of the first association of the site and the medicament to the stimulus or an ex vivo exposure of the another first association of the another site and the another medicament to the another stimulus, wherein the ex vivo exposure if implemented respectfully transforms the first association of the site and the medicament to the second association or the another first association of the another site and the another medicament to the another second association.

33. An article of manufacture for administering medicament to an animal, the article comprising:

means for encapsulating a medicament in a first medicament-release state, wherein the medicament has a first bioavailability to the animal if the article of manufacture is administered to the animal in the first medicament-release state,

the means for encapsulating a medicament in a first medicament-release state modifiable ex vivo to a second medicament-release state by an exposure to a stimulus, wherein the medicament has a second bioavailability to the animal if the article of manufacture is administered to the animal in the second medicament-release state;

the medicament;

another means for encapsulating another medicament in another first medicament-release state, wherein the another medicament has another first bioavailability to the animal if the article of manufacture is administered to the animal in the another first medicament-release state,

the another means for encapsulating another medicament modifiable ex vivo to another second medicament-release state by an exposure to another stimulus, wherein the another medicament has another second bioavailability to the animal if the article of manufacture is administered to the animal in the another second medicament-release state; and

the another medicament.